Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is licensed as a once-weekly injection, meaning a seven-day gap between doses is the schedule the clinical evidence is built on. Injecting every five days shortens that interval and steps outside the licensed regimen — something a prescriber needs to weigh in on before you change anything. The urge to adjust timing is understandable: a missed day here, a bout of nausea there, and suddenly the maths stops feeling so clean. But the seven-day cycle isn't arbitrary. It reflects the pharmacokinetics of tirzepatide (how long the active compound stays at effective levels in the body) and the safety data gathered during trials involving thousands of adults. Mounjaro is a prescription-only medicine, so any question about dosing frequency is one for the clinician who holds your prescription, not a judgement call to make alone. The NHS patient information for tirzepatide confirms the once-weekly schedule as the standard.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide has a half-life of roughly five days, which means it takes about that long for the concentration in your body to halve. The once-weekly schedule is chosen so that levels stay high enough to be effective while not accumulating to a point that increases side effects. Clinical trials (including SURMOUNT-1, published in the New England Journal of Medicine) were run on this exact schedule. The average weight reduction of around 20–21% at the highest dose is a result tied to that protocol, not to a faster cycle.
That half-life detail matters practically. If you inject on day five instead of day seven, you're adding a new dose when the previous one is still at a relatively high level. Over several weeks, that compressed schedule can push blood levels higher than the trials tested. Higher isn't automatically better, it's more likely to mean more nausea, more vomiting, or other gastrointestinal side effects during a period when you're already adjusting.
One common misconception is that injecting slightly earlier will produce faster results. The evidence doesn't support that, and our guidance on whether you can inject tirzepatide every five days explains in more detail why a shorter cycle doesn't accelerate progress. Tirzepatide works over weeks and months; shaving two days off one cycle won't change your trajectory but could make the next week harder to get through.
The Mounjaro Summary of Product Characteristics (SmPC) on the eMC does allow one narrow exception to strict weekly timing: if you miss a dose, you may inject it within four days of the missed day. After that four-day window, skip the missed dose and return to your usual schedule. That's not an invitation to routinely inject on a shorter cycle, it's a recovery provision for genuine lapses.
Outside that missed-dose window, the SmPC is clear: resume on your original weekly day and continue from there. There is no provision in the licensed guidance for a standing five-day or six-day cycle. If your lifestyle makes a fixed weekly day genuinely difficult, the right conversation is with your prescriber about finding a day that works consistently, not adjusting the interval yourself.
Our clinical team at nume reviews each patient's dosing history before any repeat prescription; changes to the schedule that fall outside the licensed guidance would be picked up at that point.
Timing drift is more common than people expect. Life intervenes (travel, illness, forgetting which day was last) and before long the gaps vary between five and nine days. A question that comes up regularly in this context is whether Mounjaro should be injected every day, and the short answer is no, it's a once-weekly medicine. The practical fix is to pick a fixed weekly day, mark it somewhere visible, and treat it like any other recurring appointment.
If you've already injected on a shorter cycle and you're wondering whether to correct back, speak to your prescriber before your next dose. They can look at when you last injected and advise on the safest way to re-establish the weekly rhythm. Some people find that questions like this come up between their regular check-ins; getting in touch with the support team is the right first step rather than trying to work it out alone.
For related questions about spacing (including what happens at the other end of the window) there's more detail on injecting every six days and on injecting every four days, both of which involve different considerations.
Your Patient Information Leaflet is the most precise reference for day-to-day questions about timing and missed doses. It's included in every Mounjaro box. If you've mislaid it, the full version is available via the eMC. The NHS tirzepatide page also covers what to do if a dose is late or forgotten in straightforward language.
For anything that feels like a clinical decision rather than a factual lookup (including whether can you inject tirzepatide every five days as an adjusted schedule) that belongs with a prescriber. You can learn more about how Mounjaro injections work in practice, including injection sites and technique. There's also a fuller overview of tirzepatide as a weight-management medicine if you're still building the picture.
If you're thinking about starting treatment or reviewing whether your current plan is right for you, checking your eligibility with our prescribers is the place to begin. Consultations are free, reviewed by a GPhC-registered Independent Prescriber, and there's no obligation to proceed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.